RBP-7000 and Relday appear to have a similar performance, but RBP-7000 requires reconstitution at the time of injection and therefore has to have needle injection. Relday does not require reconstitution and can use the needle-less injector that Zogenix offers. With needle-less injection you know for sure you are doing a subcutaneous injection--no potential lawsuits.
Everyone is speculating that Hillary is going to cause another nuclear winter like the first time she was in charge of the health care. This time she has to get elected first before she can do any damage. Her chance of election is slim and none. Besides we should have around 134million in the bank by the end of the year and 10 million more coming out of escrow early next year. Can't be in a better financial position than we are now. We have more than enough money to finish the two phase 3 trials and do some other proof of concept trials in other forms of epilepsy. There were those who were worried about IP they rolled that out in the latest Sept presentation and I did an application search and they are all there. The fact that they are not going to finance Relday on their own is a positive and should preserve significant amount of cash.
To be frank with you having the guy who has his skin in the game running the company is a plus.
time to buy
eneuro dot org slash content slash eneuro slash 2slash 4 slash ENEURO dot 0068-15 dot 2015 dot full dot pdf
Need a proof of concept study
jane first of all if you listen to the call they are not planning on developing this drug on their own what so ever. They already know they can't market this. second why are so #$%$ off? This company has so much money in the tank that there is nothing to worry about, they have only 60 people in the whole company. There is no china effect for this company, there is no dollar collapse effect for this comopany, just sunshine...
More Phase 1's on other childhood epilepsy coming. One will start 4th q. Any efficacy on this should be very positive.